Thus, it is worth exploring in future studies whether currently utilized chemotherapeutic agents such as TPT, ETO, and other chemically related drugs (e.g., irinotecan) could be repurposed as strategies to reduce Fli-1 activity and prevent or treat GVHD in the clinical setting. This evidence concerns the gene FLI1 and graft versus host disease.